Changing
the rhythm
of patient care
Simpler drug delivery.
Empowering patients.
84%
of patients want treatment at home
over hospital or clinic settings
(Becaris Publishing, 2023)
~4.6 hours
median time spent receiving treatment
including travel and clinic time
(NIH observational study, 2024)
1,000 mg
doses that have traditionally required IV
common among mAb therapies
(Drug Delivery Leader, 2025)
The Future of Biologics Shouldn’t Rely on an
Infusion Chair
Patients increasingly prefer treatments that fit into their lives, not overtake their calendars. Yet many biologic therapies still require hours in infusion centers because traditional formulations cannot achieve the concentration, stability, and injectability needed for subcutaneous delivery.
Lindy Biosciences is developing high-concentration biologic suspensions that enable subcutaneous delivery for biologics traditionally administered by IV infusion — creating new possibilities for patients, healthcare systems, and pharmaceutical innovators.
The barrier isn't the drug. It's the formulation.
What Lindy's suspensions Make Possible
A New Standard for Biologic Delivery
Many biologics remain dependent on IV administration because conventional formulations struggle to achieve the concentration, stability, and injectability needed for subcutaneous delivery. As the industry increasingly shifts toward self-administered therapies, Lindy's suspension platform helps expand what's possible for high-dose biologics.
Lindy's proprietary suspension platform takes a fundamentally different approach — enabling high-dose biologics to be delivered through standard subcutaneous injection devices while maintaining long-term stability.
The result: greater flexibility in how biologic therapies reach patients.
See the TechnologyValidated by Industry Leaders
Licensed by a Top-Five Global Pharmaceutical Company
Lindy's suspension platform is being advanced through a multi-target licensing agreement with one of the world's leading pharmaceutical innovators.
Read the Announcement
Manufacturing Pathway Established
Partnership with Lifecore Biomedical supports GMP manufacturing and future clinical development.
Read the Announcement
Built to Deliver
Deborah Bitterfield, PhD
Founder and CEO
Gary E. Vinson
Chief Operating Officer
Omar Flores, PhD, MBA
Chief Financial Officer
Neil Jones
Vice President, Corporate Strategic Partnerships
John Savage, PhD
Senior Director, Technical Operations
In the News
The latest on our science, partnerships, and progress.
.svg)
EVENTS
August 3-6, 2026
Lindy Biosciences CEO Presents at Colorado Protein Stability Conference
CEO Deborah Bitterfield, PhD, presented at the 2026 Colorado Protein Stability Conference in Breckenridge, CO, alongside leading researchers from academia, industry, and the FDA.
Read MoreEVENTS
March 2026
Deborah Bitterfield Returns to CED Venture Connect as a Featured Presenter
CEO Deborah Bitterfield, PhD, returned to CED Venture Connect (VC26) as a presenter in the Human Health – Biotech & Medtech session in Durham, NC.
Read More
In the news
February 24, 2026
Lindy Biosciences CEO Makes the Case for Subcutaneous Drug Delivery — Investment Reports
CEO Deborah Bitterfield sat down with Investment Reports to explain what Lindy Biosciences’ technology does and why it matters for patients — in plain terms.
Read More
